ypertension is a complex syndrome of multiple hemodynamic, neuroendocrine, and metabolic abnormalities. 1 The goals of treatment in hypertension are to optimally control high blood pressure and to reduce asso-control ( õ90 mm Hg ) in only about half. Combi-
H vast majority ( 90% ) have mild to moderate hypertension with diastolic blood pressure ( DBP ) 90 to 114 mm Hg, but single-drug therapy produces goal DBP ypertension is a complex syndrome of multiple hemodynamic, neuroendocrine, and metabolic abnormalities. 1 The goals of treatment in hypertension are to optimally control high blood pressure and to reduce asso-control ( õ90 mm Hg ) in only about half. Combi-nations of antihypertensive drugs are therefore Patients with alcohol or drug abuse, multiple drug allergies, or known allergy or hypersensitivity reaction common.
The combination of angiotensin converting enzyme to any ACE inhibitor, diuretic or sulfa-containing medication were excluded. (ACE) inhibitor and thiazide diuretic has been shown to have advantages over monotherapy for the treatStudy Design The 12 to 13 week study was a modiment of hypertension. 3 ACE inhibitors block the fied 4 1 4 factorial, randomized, double-blind, parallel counterregulatory rise in the angiotensin II triggered group trial of 17 different doses of the combination of by diuretic therapy; conversely, thiazide diuretic may Fos and HCTZ, comparing each of the combinations stimulate the renin-angiotensin system and enhance with the individual components and placebo. A singlethe antihypertensive action of ACE inhibitors. 4 Generblind, placebo lead-in of 4 to 5 weeks included withally, patients who do not respond adequately to ACE drawal of all antihypertensive agents and assessment inhibitor monotherapy often do respond to combinaof placebo compliance. Requirement for randomization tion therapy. An additional benefit is that the dosages to double-blind treatment was seated DBP (SeDBP) ¢95 of components in the combination can be lowered for mm Hg and°110 mm Hg at consecutive visits (third some patients, reducing the risk of dose-related adand fourth weeks, or fourth and fifth weeks) during verse effects. 2 the placebo lead-in. When two drugs are given simultaneously, a numDouble-blind treatment for 8 weeks, starting on the ber of pharmacodynamic interactions are possible inlast placebo lead-in visit (baseline), included clinic visits cluding addition, inhibition, or synergism. Precise with safety laboratory test, hematology, urinalysis, and definition of such interaction is important, as it could chemistry profile, at 2, 4, and 8 weeks after randomizaalter doses of one or both drugs in combination thertion. Eligible patients were randomized to receive comapy. A number of clinical trial designs have been used binations of 0, 2.5, 10, or 40 mg Fos and 0, 5, 12.5, or in hypertension to assess clinically significant hemo-37.5 mg HCTZ. An extra matrix group receiving 20 mg dynamic drug interactions including titration and Fos and 12.5 mg HCTZ was included to verify results crossover studies. 5, 6 Factorial design is a method for from a series of previous efficacy studies. Subjects took assessing drug interactions 7 that has been underused their first randomized, double-blind medication under in hypertension clinical trials. 8 -10 Furthermore, factosupervision in the clinic; subsequently, all study medirial design with double-blind, parallel, fixed-dose, cation was taken at this same time each day, but not and multiple groups expands the statistical options prior to their scheduled clinic visits, so that all blood available for analysis of the data. Regression models pressure measurements were made 24 { 3 h after dosusing response surface techniques and graphical preings. As part of drug safety evaluation, a subset of pasentations to maximize the descriptive data are availtients in each treatment group were evaluated for cliniable for such analyses. 11 The purpose of our study cally significant hypotension for 6 h following the first was to use these clinical trial methods to evaluate the dose. The occurrence of clinical adverse events, both efficacy and safety of various doses of the combinathose volunteered by the patients and those elicited by tion of a novel phosphinic acid ACE inhibitor, fosinogeneral questioning, and abnormalities in safety laborapril (Fos), and hydrochlorothiazide (HCTZ) in the tory tests during both the placebo and double-blind treatment of patients with mild-to-moderate hypertreatment periods were documented in detail. tension (seated diastolic blood pressure ¢95 and°1 10 mm Hg). Blood Pressure and Heart Rate Blood pressure, sys-METHODS tolic (Korotkoff phase I; first sound heard) and diastolic (phase V; disappearance of all sound), was Subjects Seven hundred and nine outpatients, who measured with a standard mercury sphygmomawere white, Asian, or black men and nonpregnant, nonnometer at least 2 h after patients abstained from lactating women (18 to 75 years of age, inclusive), with smoking tobacco or drinking alcohol and caffeinated mild-to-moderate hypertension, defined as untreated, beverages. Personnel at every center were trained seated diastolic blood pressure (SeDBP) ¢95 and°110 by a consultant in techniques for accurate blood mm Hg, were enrolled at 20 centers in the USA. The pressure measurements. Whenever possible, one obprotocol was approved by Institutional Review Boards server recorded blood pressure for an individual at for Human Research at each center, and all patients every visit, using the same arm and size cuff. After gave their informed consent. A complete physical exsitting quietly for 5 min, three initial blood pressures amination was performed at intake, including fundosand heart rates were recorded with at least 2 min copy, 12-lead electrocardiography, chest x-ray, urinalybetween readings. Next, one blood pressure and sis, hematology, and serum chemistry. All patients heart rate were repeated after 5 min of supine rest. were free of significant, major diseases including cardiovascular, renal, hepatic, and neurologic problems. Then the final measurements were made immedi- One hundred fifty-nine (22.4%) of the 709 patients enrolled in the placebo lead-in period did not qualify for randomization to double-blind therapy (Table 1) . Forty-four patients (8%) of the 550 randomized during ately and two min after standing from the supine the trial were withdrawn; 506 patients completed douposition.
ble-blind therapy. No statistically significant differences were detected among the treatment groups for Statistical Analysis Two patient populations were any demographic or baseline variable, except for baseidentified for the analysis of data from this study: 1) the line SeDBP. This difference is attributed to the 20 mg intent-to-treat population, defined as patients having Fos / 12.5 mg HCTZ group, where the mean SeDBP blood pressure data at baseline and at least one follow-was 101.2 mm Hg. When an analysis of SeDBP was up visit; and 2) the efficacy population, a subset of the rerun without the 20 mg Fos/12.5 HCTZ group, no intent-to-treat population, made up of all patients who statistically significant differences were detected did not violate any of the terms in the protocol that among the remaining treatment groups (P Å 0.98). might affect efficacy outcome. The results from both Patients were distributed evenly within each of the 17 analyses were similar, however, data based on the in-treatment groups (Table 2) . tent-to-treat population are presented here only. Separate univariate analyses were performed at 2, 4, and 8 Efficacy ANOVA Mean changes from baseline in weeks of the double-blind treatment period. The pri-SeSBP and SeDBP at week 8 are shown in Tables 3 and mary measure of efficacy was change in mean SeDBP 4, respectively. All treatment groups had significant from baseline. All hypothesis tests were two-sided and mean change from baseline SeDBP (P õ .05). The results were performed at the nominal .05 level of significance. were similar for SeSBP at week 8 (P õ .5) except for This variable was analyzed in two ways: analysis of placebo. Treatment effects (mean change for treatment variance (ANOVA) and quadratic response surface model (QRSM).
ANOVA was performed using a linear model, with / 2e11$$2119 12-08-96 19:22:36 eajha EL: AJH group minus mean change from placebo) are also selective sympatholytic agents, and became a common component of combination therapy, especially shown in Tables 3 and 4 . The addition of HCTZ to a fixed dose of fosinopril resulted in greater adjusted the evolving ''stepped-care'' regimens. Although these regimens are clearly effective, study designs mean changes from baseline for both SeDBP and seated systolic blood pressure (SeSBP) at week 8. Similarly, were often inadequate to demonstrate the details of efficacy from interactions between the individual the addition of increasing doses of fosinopril to a fixed dose of HCTZ also resulted in greater adjusted mean agents. Many of the newer antihypertensive agents, such as ACE inhibitors, made predictions about changes from baseline in SeDBP and SeSBP at week 8. particular drug interactions even more difficult, yet QRSM The response surfaces analysis of SeDBP re-these agents are often used empirically in comduction for all combinations within the range of doses binations. studied indicate a statistically significant linear dose This study, which combines factorial design and quaresponse for both fosinopril (P õ .01) and HCTZ (P õ dratic response surface analysis, has defined the antihy-.05). No statistically significant (P ú .17) interaction was pertensive dose-effect for a novel ACE inhibitor, fosinodetected between fosinopril and HCTZ, suggesting that pril, and HCTZ when administered once daily in variboth drugs in combination produced additive effects. ous combinations to patients with mild-to-moderate There was no statistically significant lack-of-fit detected essential hypertension. The randomized double-blind, at any week (P ú .18). By the first scheduled clinic visit fixed-dose, factorial, multicenter design of this study at week 2, there was evidence of reduction of blood was very effective in demonstrating 1) antihypertensive pressure from baseline pretreatment levels. Figures 1 efficacy of Fos and HCTZ when given alone or together; and 2 show predicted values (using QRSM) for SeSBP 2) the minimum dose of either drug that was necessary and SeDBP at week 8 for each of the doses used in to produce a significant reduction in blood pressure; the study. Coadministration of fosinopril and HCTZ and 3) the dose(s) of each drug to be used alone or in increased the percentage of patients who were normal-combination as initial therapy for hypertension. Both ized (SeDBP°90 mm Hg) following 8 weeks of double-agents reduced systolic and diastolic blood pressure blind therapy. Compared to the placebo group (24% in a dose-related fashion. When Fos is combined with normalized), coadministration of 10 mg Fos / 12.5 mg thiazide diuretic, its antihypertensive efficacy is addi-HCTZ (58% normalized) up to 40 mg Fos / 37.5 mg tive. Furthermore, the quadratic response surface HCTZ (77% normalized) either doubled or tripled the model for dose-effect of these two drugs at 24 h postnumber of normalized subjects.
dose could be defined. From these data, a useful twodimensional graph (Figure 3 ) could be used to predict Safety About 95% of all patients received various combinations of Fos and HCTZ that were well toler-blood pressure responses to selected dose(s) of these agents for individual patients. ated. The most common adverse events among patients were headache, cough, musculoskeletal pain, fatigue,
In conclusion, the study of combination agents for hypertension using a factorial design with quadratic upper respiratory infection, and dizziness. None of these events occurred significantly more frequently in any particular group. Nineteen patients discontinued therapy due to adverse events, including 4.3% of patients receiving combination therapy, 3.1% receiving Fos monotherapy, 1.0% receiving HCTZ, and 3.1% receiving placebo. None of these adverse events were unexpected or felt to be associated with the drugs. There were five nonfatal, serious adverse events that were all considered by the investigators to be related to underlying diseases.
DISCUSSION
After the discovery in 1948 of the hypotensive effects of mercurial diuretics on hypertensive patients, diuretics grew to be the backbone of antihypertensive therapy for the next four decades. 12 In the 1950s, when more than one type of antihypertensive drug became available, combination therapy with drugs with different modes of action began empirically starting with diuretics and sympatholytic agents. By 
